Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

AZD-6244 is beneficial in phase II trial in IRPTC and PTC

June 18, 2010

SRX-251 shows favorable safety, tolerability and pharmacokinetics in healthy subjects

June 18, 2010

Final phase II data on voreloxin/cytarabine in AML support phase III testing

June 18, 2010

Pramipexole ER shows long-term efficacy and safety in advanced Parkinson's disease

June 18, 2010

Long-term pimavanserin safe and well tolerated in Parkinson's disease psychosis

June 18, 2010

SCH-900105 is safe and advances from phase I to phase II trial

June 17, 2010

Idarubicin/busulphan improves outcome of autograft in patients with NPM1-mutant AML

June 17, 2010

GPR17 antagonist ticagrelor shows preclinical promise to treat demyelinating conditions

June 17, 2010

Endocyte presents interim phase I data on FR-targeting conjugates in solid tumors

June 17, 2010

Pridopidine beneficial in patients with Huntington's disease

June 17, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...